Scarica l'app Stockscreener
94.25
0.75%
-0.71
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$94.96
Aprire:
$94.81
Volume 24 ore:
5.01M
Relative Volume:
0.98
Capitalizzazione di mercato:
$292.26B
Reddito:
$58.07B
Utile/perdita netta:
$9.40B
Rapporto P/E:
31.30
EPS:
3.0113
Flusso di cassa netto:
$9.87B
1 W Prestazione:
+2.52%
1M Prestazione:
+4.51%
6M Prestazione:
+35.36%
1 anno Prestazione:
+41.43%
Intervallo 1D:
$94.12
$96.51
Intervallo di 1 settimana:
$89.53
$96.51
Portata 52W:
$61.24
$96.51
Astrazeneca PLC Stock (AZN) Company Profile
Nome
Astrazeneca PLC
Settore
Industria
Telefono
44 20 3749 5000
Indirizzo
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Confronta AZN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
94.26 | 294.43B | 58.07B | 9.40B | 9.87B | 3.0113 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-27 | Ripresa | Jefferies | Buy |
| 2025-10-16 | Downgrade | Deutsche Bank | Hold → Sell |
| 2025-04-15 | Iniziato | Exane BNP Paribas | Outperform |
| 2025-02-13 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-12 | Iniziato | Morgan Stanley | Overweight |
| 2024-11-20 | Aggiornamento | UBS | Sell → Neutral |
| 2024-11-06 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-16 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Sell |
| 2024-01-03 | Downgrade | Jefferies | Buy → Hold |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-09-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-07-12 | Aggiornamento | UBS | Neutral → Buy |
| 2023-07-05 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Iniziato | BMO Capital Markets | Outperform |
| 2022-09-15 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Aggiornamento | Argus | Hold → Buy |
| 2022-06-14 | Downgrade | UBS | Buy → Neutral |
| 2022-02-11 | Aggiornamento | DZ Bank | Sell → Hold |
| 2021-12-07 | Downgrade | Jefferies | Buy → Hold |
| 2021-08-12 | Ripresa | JP Morgan | Overweight |
| 2021-04-12 | Downgrade | Argus | Buy → Hold |
| 2021-03-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-02-25 | Aggiornamento | UBS | Neutral → Buy |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-12-07 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Aggiornamento | UBS | Sell → Neutral |
| 2020-11-11 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2019-11-22 | Iniziato | SVB Leerink | Outperform |
| 2019-10-25 | Aggiornamento | Liberum | Hold → Buy |
| 2019-04-02 | Downgrade | UBS | Neutral → Sell |
| 2019-02-05 | Iniziato | Exane BNP Paribas | Outperform |
| 2019-01-25 | Aggiornamento | Shore Capital | Hold → Buy |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-08-16 | Downgrade | Jefferies | Buy → Hold |
| 2018-03-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2018-02-06 | Reiterato | Leerink Partners | Mkt Perform |
| 2018-02-05 | Reiterato | Bernstein | Outperform |
| 2018-01-18 | Reiterato | Leerink Partners | Mkt Perform |
| 2017-12-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Aggiornamento | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
Mostra tutto
Astrazeneca PLC Borsa (AZN) Ultime notizie
BostonGene teams up with AstraZeneca on AI-driven oncology - The Pharma Letter
BostonGene, AstraZeneca Partner to Advance Oncology Drug Development - Contract Pharma
Check out AstraZeneca PLC's stock price (AZN-GB) in real time - CNBC
Check out AstraZeneca PLC's stock price (AZN) in real time - CNBC
AstraZeneca PLC (AZN) Stock Analysis: A Healthcare Giant With 8% Upside Potential - DirectorsTalk Interviews
AstraZeneca stock hits all-time high at 94.02 USD - Investing.com
AstraZeneca stock hits all-time high at 94.02 USD By Investing.com - Investing.com South Africa
JP Morgan expects solid AstraZeneca quarter and reassuring outlook - Proactive financial news
AstraZeneca's (AZN) Saphnelo Shows Promising Phase III Results - GuruFocus
AstraZeneca's Self-Injectable Lupus Drug Shines In Late-Stage Trial - Benzinga
Astrazeneca Study Shows Saphnelo Injection Reduces Lupus Disease Activity - marketscreener.com
Eyes on Asia: Insilico, Ipsen, AstraZeneca - BioXconomy
AstraZeneca flags positive trial data for Saphnelo as SLE treatment - marketscreener.com
Haleon Shares Added, AstraZeneca Removed From Goldman Sachs European Conviction List - AskTraders.com
AstraZeneca says Saphnelo SC showed significant reduction in lupus disease activity - marketscreener.com
G-Protein Coupled Receptors (GPCRs) Market Size to Hit USD 6.04 Billion by 2032, Growing at a CAGR of 5.59% - GlobeNewswire Inc.
AstraZeneca (AZN) Dropped from Goldman Sachs' European Convictio - GuruFocus
AstraZeneca PLC $AZN Stake Boosted by Allspring Global Investments Holdings LLC - MarketBeat
The Truth About AstraZeneca plc: Why Everyone Is Suddenly Paying Attention - AD HOC NEWS
Can AstraZeneca PLC ZEG stock sustain institutional flowsMarket Weekly Review & Daily Stock Trend Reports - moha.gov.vn
Key facts: AstraZeneca lowers drug prices for Medicaid; reports share count - TradingView — Track All Markets
AstraZeneca reports total voting rights of 1.55 billion shares - Investing.com
AstraZeneca reports total voting rights of 1.55 billion shares By Investing.com - Investing.com South Africa
Biological Therapies for Cancer Global Markets Report 2025-2030: Merck, BMS, Roche, AstraZeneca, Johnson & Johnson, and Novartis Drive Growth Through Pipeline Expansion and Strategic CollaborationsResearchAndMarkets.com - FinancialContent
Q4 EPS Estimates for AstraZeneca Boosted by Zacks Research - MarketBeat
My Personal CFO LLC Acquires Shares of 38,411 AstraZeneca PLC $AZN - MarketBeat
Zacks Research Raises Earnings Estimates for AstraZeneca - MarketBeat
25,322 Shares in AstraZeneca PLC $AZN Purchased by Moody Lynn & Lieberson LLC - MarketBeat
The Zacks Analyst Blog Highlights Berkshire Hathaway, AstraZeneca, Intel, Kingsway Financial and BK Technologies - Yahoo Finance
Smith Salley Wealth Management Raises Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
Top Stock Reports for Berkshire Hathaway, AstraZeneca & Intel - Nasdaq
Ethic Inc. Acquires 11,638 Shares of AstraZeneca PLC $AZN - MarketBeat
Why AstraZeneca PLC (Common Stock) (ZEGA) stock appears on watchlistsHigh Frequency Trading Trends & Free Powerful Profit Generation - bollywoodhelpline.com
Valicenti Advisory Services Inc. Has $4.66 Million Holdings in AstraZeneca PLC $AZN - MarketBeat
DAVENPORT & Co LLC Increases Stake in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC (AZN) Stock Price Today - CoinMarketCap
AstraZeneca stock holds steady as mixed news and technicals limit major moves - Traders Union
Robbins Farley Purchases 27,582 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca Reaches Settlement With MSN Labs Over Cancer Drug - Bloomberg Law News
Swedbank AB Buys 286,904 Shares of AstraZeneca PLC $AZN - MarketBeat
LSEG, Rolls-Royce, AstraZeneca and Rightmove spotlighted as investment bank eyes potential winners for 2026 - Proactive financial news
Here's Why Astrazeneca (AZN) is a Strong Value Stock - Yahoo Finance
AstraZeneca’s NSCLC combo fails to meet primary endpoint in Phase III trial - Clinical Trials Arena
FDA Flags Deadly Risks, AstraZeneca Pulls Andexxa From US Market - Sahm
AstraZeneca's Lung Cancer Combo Falls Short In Phase 3 Trial - Sahm
Jacobio signs $1.9B deal with Astrazeneca for pan-KRAS inhibitor - BioWorld MedTech
AstraZeneca Sues US Over Drugs for Medicare Price Cuts Round 2 - Bloomberg Law News
AstraZeneca (AZN) to Withdraw Andexxa from U.S. Market by Year's End - GuruFocus
AstraZeneca reports Phase III trial of ceralasertib and Imfinzi did not meet main goal - Investing.com Nigeria
AstraZeneca’s Synthetic Lethality Drug Combo Fails In Phase III Trial - Citeline News & Insights
AstraZeneca director Nazneen Rahman sells 297 shares in London transaction - Investing.com
Astrazeneca PLC Azioni (AZN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):